Ono Pharmaceutical Co (Ono Pharmaceutical Co) GF Value Rank : 8 (As of Apr. 28, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Ono Pharmaceutical Co GF Value Rank?

Ono Pharmaceutical Co has the GF Value Rank of 8.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Ono Pharmaceutical Co's GF Value Rank

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ono Pharmaceutical Co's GF Value Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's GF Value Rank falls into.

Ono Pharmaceutical Co GF Value Rank Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLY) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

OPHLF:USA 4528:Japan ON4:Germany

Address

8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564

Website

http://www.ono.co.jp

Ono Pharmaceutical is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a global business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.

Ono Pharmaceutical Co (Ono Pharmaceutical Co) Headlines

From GuruFocus

Ono Pharmaceutical Co Stock Appears To Be Modestly Undervalued

By GF Value • 07-05-2021

T. Rowe Price Japan Fund Purchases 5 Stocks in 3rd Quarter

By Holly LaFon Holly LaFon • 10-18-2017

Samuel Isaly's Eaton Vance Worldwide Health Sciences Fund Q1 Investment Report

By Holly LaFon Holly LaFon • 05-13-2016

Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million

By PRNewswire • 12-01-2023